RUBICON RESEARCH PRIVATE LIMITED

Rubicon Research Secures ₹250 Crore Pre-IPO Investment from Amansa, Reduces Fresh Issue Size Ahead of Year-End Public Listing

- Amansa Investments has completed a ₹250 crore pre-IPO investment in pharmaceutical formulations company Rubicon Research, acquiring shares at ₹484.47 per share. - The investment reduces Rubicon Research's fresh IPO issue size from ₹500 crore, with the company expected to launch its maiden public offering by the end of 2024. - General Atlantic Singapore remains the majority shareholder with 54.01% stake after transferring 51.60 lakh equity shares to Amansa Investments. - Rubicon Research operates two US FDA-inspected R&D facilities and maintains a portfolio of 69 USFDA-approved products targeting regulated markets, particularly the United States.